×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| NEULAND LABORATORIES LTD. | 3006.09 | 137.08 | 2927.53 | 10.68 | 18,411 | 140.0 |
| 530019 | 602.0 | 58.0 | 595.0 | 0.26 | 17682 | 36.4 |
| Concord Biotech Limited | 2176.65 | 425.65 | 2039.88 | 4.07 | 16852 | 47.3 |
Neuland Laboratories Limited., with Security Code 524558, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 407.1 | 363.0 | 417.7 | 392.8 | 385.0 | 439.6 | 310.8 | 398.0 | 328.4 | 292.8 |
| Expenses | 287.4 | 265.7 | 280.5 | 272.3 | 278.2 | 315.8 | 249.5 | 311.7 | 277.6 | 258.5 |
| Operating Profit | 119.7 | 97.3 | 137.3 | 120.6 | 106.8 | 123.8 | 61.3 | 86.4 | 50.8 | 34.3 |
| OPM % | 29.41% | 26.8% | 32.87% | 30.69% | 27.74% | 28.17% | 19.73% | 21.7% | 15.47% | 11.71% |
| Other Income | 8.1 | 2.0 | 3.0 | 2.1 | 5.4 | 25.4 | 4.3 | 59.7 | 7.5 | 7.9 |
| Interest | 4.3 | 2.2 | 4.4 | 3.7 | 3.6 | 2.7 | 1.1 | 2.2 | 2.3 | 4.6 |
| Depreciation | 13.5 | 13.6 | 14.5 | 15.1 | 16.5 | 16.3 | 16.1 | 16.3 | 16.9 | 20.2 |
| Profit before tax | 110.0 | 83.5 | 121.4 | 103.8 | 92.1 | 109.7 | 48.5 | 71.8 | 39.0 | 17.4 |
| Tax % | -23.2% | -25.5% | -26.6% | -22.2% | -26.6% | -24.5% | -34.2% | -20.5% | -28.7% | 21.1% |
| Net Profit | 84.5 | 62.2 | 89.1 | 80.7 | 67.6 | 98.3 | 32.0 | 101.4 | 27.7 | 13.7 |
| EPS in Rs | 65.87 | 48.5 | 69.42 | 62.9 | 52.7 | 76.65 | 24.91 | 79.03 | 0 | 10.68 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 269.3 | 407.1 | 363.0 | 417.7 | 392.8 | 385.0 | 439.6 | 310.8 | 398.0 | 328.4 |
| Expenses | 215.2 | 287.2 | 266.1 | 280.3 | 271.6 | 278.1 | 316.2 | 248.6 | 311.4 | 277.3 |
| Operating Profit | 54.1 | 119.9 | 96.9 | 137.5 | 121.3 | 106.9 | 123.4 | 62.2 | 86.6 | 51.1 |
| OPM % | 20.09% | 29.44% | 26.7% | 32.91% | 30.87% | 27.77% | 28.06% | 20.02% | 21.76% | 15.56% |
| Other Income | 0.9 | 8.1 | 2.0 | 3.0 | 2.1 | 5.4 | 25.4 | 4.3 | 59.7 | 7.5 |
| Interest | 2.7 | 4.3 | 2.2 | 4.4 | 3.7 | 3.6 | 2.7 | 1.1 | 2.2 | 2.3 |
| Depreciation | 13.3 | 13.5 | 13.6 | 14.5 | 15.1 | 16.5 | 16.3 | 16.1 | 16.3 | 16.9 |
| Profit before tax | 38.9 | 110.2 | 83.2 | 121.6 | 104.5 | 92.2 | 109.2 | 49.4 | 72.0 | 39.3 |
| Tax % | -21.5% | -23.3% | -25.6% | -26.6% | -22.1% | -26.7% | 24.6% | 33.5% | 20.5% | -29% |
| Net Profit | 30.5 | 84.5 | 61.9 | 89.2 | 81.4 | 67.6 | 97.9 | 32.8 | 101.6 | 27.8 |
| EPS in Rs | 23.81 | 65.9 | 48.23 | 69.56 | 63.44 | 52.66 | 76.28 | 25.6 | 79.18 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 14% |
| 3 Years: | 16% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 67% |
| 3 Years: | 46% |
| TTM: | -33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 41% |
| 5 Years: | 91% |
| 3 Years: | 122% |
| 1 Year: | 80% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 14% |
| 3 Years: | 16% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 66% |
| 3 Years: | 46% |
| TTM: | -33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 41% |
| 5 Years: | 91% |
| 3 Years: | 122% |
| 1 Year: | 80% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|